Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Onconova Therapeutic (ONTX)

Onconova Therapeutic (ONTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 76,380
  • Shares Outstanding, K 15,781
  • Annual Sales, $ 230 K
  • Annual Income, $ -25,160 K
  • 60-Month Beta 1.74
  • Price/Sales 329.28
  • Price/Cash Flow N/A
  • Price/Book 2.50
Trade ONTX with:

Options Overview

Details
  • Implied Volatility 112.42%
  • Historical Volatility 41.93%
  • IV Percentile 7%
  • IV Rank 5.84%
  • IV High 264.95% on 07/29/21
  • IV Low 102.95% on 07/20/21
  • Put/Call Vol Ratio 0.50
  • Today's Volume 3
  • Volume Avg (30-Day) 53
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 60
  • Open Int (30-Day) 225

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.26
  • Number of Estimates 2
  • High Estimate -0.20
  • Low Estimate -0.32
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +42.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.43 +9.93%
on 08/20/21
5.63 -13.50%
on 08/31/21
+0.15 (+3.18%)
since 08/16/21
3-Month
4.43 +9.93%
on 08/20/21
7.52 -35.24%
on 06/24/21
-2.36 (-32.64%)
since 06/16/21
52-Week
3.53 +38.04%
on 09/17/20
28.95 -83.18%
on 02/18/21
+1.23 (+33.66%)
since 09/16/20

Most Recent Stories

More News
Onconova Therapeutics Announces Participation at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will...

ONTX : 4.87 (+0.62%)
Onconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Tops Revenue Estimates

Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of 3.57% and 35.71%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?...

ONTX : 4.87 (+0.62%)
Onconova Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial...

ONTX : 4.87 (+0.62%)
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2021 Financial Results on August 12, 2021

Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the...

ONTX : 4.87 (+0.62%)
Will Onconova Therapeutics, Inc. (ONTX) Report Negative Q2 Earnings? What You Should Know

Onconova Therapeutics, Inc. (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ONTX : 4.87 (+0.62%)
Global Brain Tumor Diagnosis & Treatment Market Could Exceed $880 Million By 2027

PALM BEACH,  Fla., /PRNewswire/ -- Cancer is a foremost public health problem globally and is the second leading cause of death in the United States.  According to the National Brain Tumor Society,...

CNSP : 1.5300 (-1.29%)
MNKD : 4.56 (-2.36%)
ITRM : 0.6030 (-0.12%)
ONTX : 4.87 (+0.62%)
PFE : 44.47 (-0.67%)
Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer

Expansion of trial underway at highest dose in the current protocol, and continued dose escalation under consideration

ONTX : 4.87 (+0.62%)
Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that on June 17, 2021 it received...

ONTX : 4.87 (+0.62%)
Onconova Therapeutics Announces the Peer-Reviewed Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Rigosertib Combined with Immune Checkpoint Blockade

Rigosertib synergistically combined with immune checkpoint blockade (ICB) to improve tumor growth inhibition and survival in a murine melanoma model that did not respond to ICB alone

ONTX : 4.87 (+0.62%)
Thinking about buying stock in Irving Resources, Soligenix, Exela Technologies, Soleno Therapeutics, or Onconova Therapeutics?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IRV, SNGX, XELA, SLNO, and ONTX.

IRVRF : 0.9198 (+5.12%)
IRV.CN : 1.160 (+0.87%)
ONTX : 4.87 (+0.62%)
SLNO : 0.9210 (+1.68%)
SNGX : 1.0600 (-3.64%)
XELA : 2.10 (+1.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV,...

See More

Key Turning Points

3rd Resistance Point 5.18
2nd Resistance Point 5.06
1st Resistance Point 4.97
Last Price 4.87
1st Support Level 4.76
2nd Support Level 4.64
3rd Support Level 4.55

See More

52-Week High 28.95
Fibonacci 61.8% 19.24
Fibonacci 50% 16.24
Fibonacci 38.2% 13.24
Last Price 4.87
52-Week Low 3.53

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar